Skip to content

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Aug 2026 · Hepatology Research · Vol 56, pp. 1535-1546 · 0 citations · 32 references
Medicine

TL;DR

CKD-related outcomes were more strongly associated with the burden of cardiometabolic abnormalities than with hepatic steatosis itself, and these associations were consistent in individuals with and without SLD.

Abstract

Aim

Although steatotic liver disease (SLD) has been associated with chronic kidney disease (CKD), it remains unclear whether CKD-related outcomes are driven by hepatic steatosis itself or by accompanying cardiometabolic abnormalities. We investigated the relative contribution of hepatic steatosis and cardiometabolic risk factors to CKD-related outcomes using a large Japanese health screening cohort.

Methods

In total, 30,648 SLD and 76,182 non-SLD participants enrolled in the MIRACLE-J cohort across 13 centers in Japan between 2014 and 2018 were analyzed. CKD-related outcomes were defined as reduced estimated glomerular filtration rate (eGFR< 60 mL/min/1.73 m2) and proteinuria. Multivariable logistic regression and trend analyses were performed to identify factors associated with these outcomes.

Results

Compared with non-SLD participants, those with SLD exhibited a higher burden of cardiometabolic abnormalities. Type 2 diabetes mellitus, obesity, and hyperuricemia were independently associated with proteinuria, whereas advanced age (≥ 65 years), low alcohol intake, and hyperuricemia were strongly associated with reduced eGFR. After multivariable adjustment, SLD showed an inverse association with CKD-related outcomes. In both SLD and non-SLD populations, the prevalence of CKD-related outcomes increased stepwise with a higher number of cardiometabolic risk factors. Incorporation of hyperuricemia significantly improved model fit for reduced eGFR (Δ-2 log likelihood = 119.4, p < 0.001) and modestly improved model fit for proteinuria (p = 0.002).

Conclusions

CKD-related outcomes were more strongly associated with the burden of cardiometabolic abnormalities than with hepatic steatosis itself, and these associations were consistent in individuals with and without SLD. Hyperuricemia provided incremental value for renal risk stratification within this cardiometabolic framework, underscoring the importance of comprehensive metabolic risk assessment beyond liver fat status.

View source

Similar papers

Sep 2026

Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum.

A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.

Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al. · 0 citations
Review Open access Sep 2026

Association of MASLD with chronic kidney disease according to metabolic profiles and fibrosis severity: a KNHANES analysis

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem metabolic disorder with extrahepatic manifestations, including chronic kidney disease (CKD). However, population-level evidence on the renal impact of metabolic heterogeneity and fibrosis severity in...

Hyejin Park, S. Kim · 0 citations
Review Open access Sep 2026

Associations of metabolic dysfunction-associated steatotic liver disease and significant fibrosis phenotypes with glomerular hyperfiltration defined by indexed eGFR

Background To examine associations of metabolic dysfunction-associated steatotic liver disease (MASLD) and significant fibrosis with glomerular hyperfiltration (GHF) defined from indexed estimated glomerular filtration rate (eGFR), accounting for body size. Methods We analyzed 9,140 NHANES participants and 721 adults f...

Wen Tian, Jia-Meng Wang, Xue-Ling Xu et al. · 0 citations
Review Oct 2026

B-247 Associations between renal function, hepatic fibrosis indices, and metabolic biomarkers across two decades of NHANES data

In a large, nationally representative cohort, renal function exhibited stable and significant inverse associations with non-invasive hepatic fibrosis indices across nearly two decades, highlighting population-level coupling between kidney function, hepatic risk scores, and metabolic traits.

Amr Elhamamsy, Yu-Sheng Zhu · 0 citations
Open access Aug 2026

Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease

Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile, and an elevated HSI score, suggesting steatosis, was associated with dyslipidemia, and an elevated NFS score, suggesting fibrosis, was not.

Laura A. M. Konings, Weiwei Xu, Vivian D. de Jong et al. · 0 citations
Review Sep 2026

Cumulative metabolic burden and urinary albumin-to-creatinine ratio in non-diabetic adults: a nationwide population-based study.

The findings should be interpreted as hypothesis-generating and suggest that adults without diabetes but with clustered metabolic abnormalities may warrant further longitudinal evaluation for kidney risk stratification.

Xiao-Han Xu, Shan-Hu Qiu, Xiao-Ying Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.